Clinical trial
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)
NCT02502981 is registered in ClinicalTrials.gov with University Hospital Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)
- Lead sponsor
- University Hospital Birmingham
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- June 30, 2014
- Completion date
- May 31, 2018
- Enrollment
- 154 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.